PTP1B-IN-9

Research use only, not for human use.

PTP1B-IN-9 is a ubiquitin-proteasome system (UPS)-stressor,with anticancer activity. PTP1B-IN-9 reduces the cell viability of exponentially growing HeLa cervical cancer cells in a dose-dependent fashion with an IC50 value of 2 μM[1].

PTP1B-IN-9 is a ubiquitin-proteasome system (UPS)-stressor,with anticancer activity. PTP1B-IN-9 reduces the cell viability of exponentially growing HeLa cervical cancer cells in a dose-dependent fashion with an IC50 value of 2 μM.

RAMB4 (0-30 μM; 48 hours) treatment produces a dose dependent reduction in the viability of HPV16-positive SiHa and Caski cells and HPV-39-positive ME180 cervical cancer cell lines respectively.RAMB4 reduces the cell viability of exponentially growing HeLa cervical cancer cells in a dose-dependent fashion with an IC50 value of 2 μM. Cell Viability Assay Cell Line:Keratinocytes, SiHa, CaSki and ME180 cells Concentration:5, 10, 15, 20, 25, 30 μM Incubation Time:48 hours Result:Produced a dose dependent reduction in the viability of HPV16-positive SiHa and Caski cells and HPV-39-positive ME180 cervical cancer cell lines respectively with minimal effects on the viability of primary human keratinocytes and with IC50 similar to the obtained with HeLa cells.

——

——

Proteasome/Ubiquitin

Proteasome

Proteasome

——

——

145888-79-5

413.1

C19H13Cl4NO?

>98% (HPLC)

In Vitro:?DMSO : 5 mg/mL (12.10 mM)

ClC1=CC=C(\\C=C2/CNC\\C(=C/C3=CC(Cl)=C(Cl)C=C3)C2=O)C=C1Cl

——

(-20℃)

With Ice Pack

≥ 2 years